Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease (WILLACT)

Fondation Ophtalmologique Adolphe de Rothschild

Status: Enrolling

Conditions: Wilson's Disease

Treatments: Other: Patients with Wilson's disease declaring pregnancy,

Study type: Interventional

Funder types: NETWORK

Identifiers

NCT05183165

AOA_2021_28

Details and patient eligibility

About

Wilson's disease is a rare genetic disease, affecting less than 1,500 people in France. The transmission is autosomal recessive linked to an anomaly of the ATP7B gene on chromosome.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member. If there is no mutation, this ATPase incorporates copper into apo-ceruloplasmin to be released into the blood serum. The mutation of the ATP7B gene results in a defective biliary excretion of copper, leading to its accumulation in the liver, but also in other organs such as the eye or the brain. Advances in treatment have dramatically changed the prognosis for Wilson's disease, making the desire for pregnancy more confident.

The consensus is to maintain treatment during pregnancy, reducing the dosage to limit teratogenicity as well as the risk of fetal copper deficiency.The mammary gland is the primary site of copper metabolism in lactation, and ATPase 7B is the primary effector.

It has been shown in a mouse model of Wilson's disease (ATP7B - / - mouse) with treatment, that mothers accumulate copper in the liver but also in the mammary gland.

However, a recent study showed that the copper level in breast milk was normal in 18 Wilsonian patients treated with D-penicillamine, trientine salts or zinc salts, suggesting that breastfeeding is possible in these patients without risk to the development of the infants.The problem of breastfeeding newborns for patients with Wilson's disease is therefore associated with a risk of copper deficiency in the newborn due to insufficiently rich breast milk in copper due to drugs.

In addition, the passage into breast milk of treatments is not sufficiently known.

These factors make breastfeeding not currently recommended for Wilsonian mothers,However, many patients wish to breastfeed and some of them breastfeed their newborns despite the risk of breastfeeding

Enrollment: 15 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Criteria for inclusion :

• Patient aged 18 years or over.
• Wilson's disease fulfilling the criteria for the Leipzig score
• Pregnancy in progress whatever the term.
• Express consent to participate in the study.
• Affiliate or beneficiary of a social security system.

Criteria for non-inclusion :

• Liver transplant patient
• No affiliation to Social Security system
• VuInability to give free and informed consent
• Patient benefiting from a legal protection measure

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

Patients with Wilson's disease declaring pregnancy,

Other group

Description:

Patients with Wilson's disease declaring pregnancy.Followed in the reference, constituent, and competence centers for Wilson's disease and other rare copper-related diseases, spread over French national territory.

Treatment:

Other: Patients with Wilson's disease declaring pregnancy,